In this study, we identified EGCG as a potentially safe and effective agent for use with gemcitabine in the blocking of pancreatic cancer migration and invasion partly by inhibiting the Akt pathway and EMT. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.